2 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Progression: new trials by email Literature Review of Progression trials Research Report on Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omitting CTV for Primary Tumor in LS-SCLC Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor - SCLC, Limited Stage, Radiation Exposure | Phase 3 | Recruiting | Sun Yat-sen University | 852 | 2025-06-03 | 2025-06-06 |
| Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression HCQ - Covid19, Progression | Phase 3 | Completed | UNICEF | 540 | 2020-04-10 | 2020-08-21 |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Temozolomide, Bevacizumab - Glioblastoma, Recurrence | Phase 3 | Completed | Kyorin University | 146 | 2016-07-11 | 2026-08-07 |
Disease Progression (3) · COVID-19 (1) · Glioblastoma (1) · Radiation Injuries (1) · Recurrence (1)
Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Astrocytoma (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Glioma (1) · Infections (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1)
Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Etoposide (1) · Hydroxychloroquine (1) · Radiotherapy (1) · Standard of Care (1) · Temozolomide (1)
Kyorin University (1) · Sun Yat-sen University (1) · UNICEF (1)
China (1) · Japan (1) · Pakistan (1)